Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

NEW YORK, Oct. 9, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

http://www.reportlinker.com/p0619272/Healthcare-Acquired-Infection-Devices-Pharmaceuticals-and-Environmental-Products.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply

REASONS FOR DOING THE STUDY

The objective of this study is to provide an in-depth analysis and forecast of selected areas of the global healthcare-acquired infections (HAI) market. For purposes of this report, HAI includes hospitals, nursing homes, outpatient surgery centers and dialysis centers. The focus of this report is on selected devices, pharmaceuticals and environmental products currently used or under development for treatment of viral, bacterial and fungal infections.The global market for HAI products is estimated at between $12 billion and $17 billion in 2012 (depending on the products included in the study) with high single-digit growth through 2018. The North American market and in particular the U.S. holds the largest market share of any region at 45% to 50% and the fastest growing regions for HAI treatments are Brazil and the Asian region, particularly China and India.

STUDY GOALS AND OBJECTIVES

Healthcare-acquired infections are viral, bacterial or fungal infections that patients acquire after they are admitted to a healthcare facility. Patients can acquire these infections from routine care; surgery; or as a complication from the use of medical devices such as ventilators, catheters and intravenous lines.This report is designed to investigate the global HAI market by treatment area and by type of treatment, with supporting tables and figures to illustrate projected growth. Within each type of treatment, regional analyses will focus on the Americas (i.e., Canada, U.S., Mexico, Central America and South America); EMRA (i.e., Europe, the Middle East, Russia and Africa); and Asia (i.e., Japan, China, India, other Western Pacific countries such as Australia and New Zealand and other Southeast Asian countries).

SCOPE AND FORMAT

This report offers forecasts by treatment segment and type of treatment, from 2013 through 2018, including supporting analyses for projections.The main market segments are analyzed by pharmaceutical treatments, environmental treatments and infection control devices/products.This report is a valuable tool for anyone assessing the HAI market and attempting to devise a strategy to successfully compete in this market. This report provides background on the structure of the HAI market and the chief challenges and opportunities it faces. It offers the information needed to understand the current market and to address the emerging one.The report is an invaluable tool for business planners, acquisition specialists, licensing strategists, product managers, market research analysts, investing consultants and others interested in the HAI market, its products, its participants and its future.

METHODOLOGIES AND INFORMATION SOURCES

Information for this report was obtained from a variety of primary and secondary research sources, including industry analysts, annual reports and agencies and organizations such as the U.S. Securities and Exchange Commission (SEC), the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), the U.S. National Institutes of Health (NIH), American Hospital Association (AHA), Infectious Disease Society of America (IDSA), American Society of Heating, Refrigerating and Air Conditioning Engineers (ASHRAE), National Institute of Allergy and Infectious Diseases (NIAID), the National Hospital Discharge Survey (NHDS) and government agencies outside the U.S. Secondary sources include literature searches, journal articles, product literature and press releases.When precise information was not available, a consensus has been made using reasonable assumptions and estimates based on historical data.

ANALYST CREDENTIALS

Peggy S. Lehr is the BCC Research Analyst of this report. Ms. Lehr holds a BS in Journalism from the University of Colorado, Boulder and an MS in Communication from the University of Denver. Ms. Lehr has worked within the publishing industry for both for-profit and not-for-profit organizations and she specializes in marketing reports on the medical industry. Her latest report, HLC078B Magnetic Resonance Imaging: The Global Market, was published in September 2013.

REPORT HIGHLIGHTS

This report provides:• Forecasts of the markets for healthcare-acquired infection (HAI) devices, pharmaceuticals, and therapies by treatment segment and treatment type, including supporting analyses for projections• Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018• Valuable tools for anyone assessing the HAI market and attempting to devise a strategy to successfully compete in the industry• Background on the structure of the HAI market and the opportunities available as well as the chief challenges it faces• Information needed to understand the current market and to address the emerging market• Comprehensive company profiles of key players in the market.

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

REASONS FOR DOING THE STUDY 2STUDY GOALS AND OBJECTIVES 2SCOPE AND FORMAT 2METHODOLOGIES AND INFORMATION SOURCES 3ANALYST CREDENTIALS 3RELATED BCC REPORTS 3BCC ONLINE SERVICES 3DISCLAIMER 4

CHAPTER 2 SUMMARY 6

SUMMARY TABLE GLOBAL MARKET FOR SELECTED HAI TREATMENTS, THROUGH2018 ($ MILLIONS) 7SUMMARY FIGURE GLOBAL MARKET SHARES OF HAI TREATMENTS BYGEOGRAPHICAL AREA, 2013 AND 2018 (%) 8

CHAPTER 3 GLOBAL HAI OVERVIEW 10

RISKS FOR ACQUIRING HAI 10MOST COMMON HEALTHCARE-ASSOCIATED INFECTIONS 11TABLE 1 CAUSES AND TYPES OF HEALTHCARE-ACQUIRED INFECTIONS 12GRAM-POSITIVE BACTERIA 13S. AUREUS 13Transmission Routes 13MRSA 13Transmission Routes 14PNEUMONIA 14Pseudomonas Aeruginosa 14Hospital-Acquired Pneumonia (HAP) 14K. Pneumonia 14CLOSTRIDIUM DIFFICILE 15MYCOBACTERIUM TUBERCULOSIS 15TB Funding 15Scope of Infection 15Multi-Drug Resistant Tuberculosis (MDR-TB) 16E. COLI 16UTI Treatment Options 16GASTROENTERITIS-CAUSING BACTERIA 17Treatment Options 17VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE) 17Types of VRE 17LEGIONELLA BACTERIA 17Treatment Options 18GRAM-NEGATIVE BACTERIA 18PSEUDOMONAS AERUGINOSA 18ACINETOBACTER BAUMANNII 18CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) 19VIRAL INFECTIONS 19HEPATITIS B AND C 19Scope of Infection 19Treatment 20HIV 20Treatment 20NOROVIRUS 20INFLUENZA VIRUS 21Influenzavirus A, B, C 21Transmission 21Symptoms 21Treatment 21FUNGAL INFECTIONS 22ASPERGILLUS INFECTIONS 22Treatment 22YEAST INFECTIONS 22Candida Infections 23PREVENTING HAI 23DETERMINING THE MODE OF TRANSMISSION 23ROLES OF HEALTHCARE INSTITUTIONS AND INFECTION CONTROLINDIVIDUALS 24TABLE 2 SELECTED RESPONSIBILITIES OF INFECTION CONTROL TEAM MEMBERS 24COMPONENTS OF A HAI SURVEILLANCE SYSTEM 26TABLE 3 MAIN STEPS AND COMPONENTS IN DEVELOPING AN EFFECTIVE INFECTIONCONTROL SURVEILLANCE SYSTEM 26HEALTHCARE INFECTION POINTS OF GENERATION 27HOSPITAL 27Hospital Surgical Procedures 27AMBULATORY SURGERY CENTERS IN THE U.S. 27Infection Control in ASCs 28DIALYSIS CENTERS 28Transmission of VRE in Dialysis Centers 28Hepatitis Transmission in Dialysis Centers 29ASSISTED LIVING/LONG-TERM CARE FACILITIES 29PROACTIVE TREATMENTS 29THE IMPORTANCE OF HAND WASHING 29CDC RECOMMENDATIONS FOR PREVENTION 30TABLE 4 CDC MEASURES FOR PREVENTION OF HEALTHCARE-ACQUIREDINFECTIONS 30TABLE 5 GOALS TO REDUCE HAI IN U.S. HOSPITALS BY 2013 32TABLE 6 DECREASE IN HAI IN U.S. HOSPITAL SETTINGS, 2008–2010 (%) 32ENVIRONMENTAL CONTROLS 32DEVICE DESIGN 33HUMAN AND MONETARY COSTS OF HAI 33U.S. HEALTHCARE SPENDING 33U.S. HEALTHCARE SPENDING AND HAI 33EMRA 34ASIA 34India 34Japan 34Rate of Infection 35CHINESE MARKET 35CHANGES IN THE INDUSTRY 36TABLE 7 SELECTED MERGERS AND/OR ACQUISITIONS, 2008-2013 ($ MILLIONS) 36

CHAPTER 4 HAI PHARMACEUTICAL MARKET 39

PHARMACEUTICALS USED FOR HAI 39TABLE 8 PROJECTED GLOBAL MARKET FOR HAI PHARMACEUTICALS BY TYPE,THROUGH 2018 ($ MILLIONS) 39VIRAL HAI PHARMACEUTICALS 40TABLE 9 SELECTED VIRAL HAI PHARMACEUTICALS BY NAME, INDICATION ANDMANUFACTURER, 2010 40VIRAL PHARMACEUTICAL MARKET BY COMPANY 41FIGURE 1 ESTIMATED GLOBAL MARKET SHARES OF HEPATITIS PHARMACEUTICALSTO TREAT HAI BY COMPANY, 2012 (%) 41FIGURE 2 ESTIMATED GLOBAL MARKET SHARES OF HIV PHARMACEUTICALS TOTREAT HAI BY COMPANY, 2012 (%) 42FIGURE 3 GLOBAL MARKET SHARES OF HAI VIRAL PHARMACEUTICALS BY TYPE OFDISEASE, 2012 (%) 43VIRAL PHARMACEUTICAL MARKET BY CONDITION 43TABLE 10 PROJECTED GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT VIRALHAI BY CONDITION, THROUGH 2018 ($ MILLIONS) 44BACTERIAL HAI 44THE THREAT OF ANTIBIOTIC RESISTANCE 44THE MICROBIOLOGY OF BACTERIAL RESISTANCE 44MECHANISMS OF RESISTANCE 45METHODS OF RESISTANCE 45Beta-Lactamase Production 45Importing Resistance from Other Organisms 46Alteration of Binding Sites to Circumvent Anti-infective Effectiveness 47Antibiotic Discharge 47PRIMARY REASONS FOR ANTIBIOTIC RESISTANCE 47Incomplete Course of Prescribed Medicine 47Overuse of Broad-Spectrum Antibiotics 47Antibiotics and Food Production Animals 48Patient Pressure 48RESISTANCE BY CLASS OF ANTIBIOTIC 48TABLE 11 ANTIBIOTIC RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED 49BACTERIAL HAI PHARMACEUTICALS 49TABLE 12 SELECTED BACTERIAL HAI PHARMACEUTICALS BY NAME, INDICATIONAND MANUFACTURER, 2012 49CLASSES OF DRUGS 50Aminoglycosides 50B-lactam Antibiotics 51Cephalosporins 51Glycopeptides 52Lincosamides 52Lipopeptides 52Carbapenems 52Penicillins 53Polypeptides 53Macrolides 53Quinolones 53Tetracyclines 54Sulfonamides 54Other Formulations 54New Treatment for Tuberculosis 54GLOBAL MARKET SHARE FOR BACTERIAL PHARMACEUTICALS BY COMPANY 54FIGURE 4 ESTIMATED GLOBAL MARKET SHARES OF HAI BACTERIALPHARMACEUTICALS BY COMPANY, 2012 (%) 54TABLE 13 PROJECTED GLOBAL MARKET FOR TO TREAT BACTERIAL HAI, THROUGH2018 ($ MILLIONS) 56FUNGAL HAI PHARMACEUTICALS 56TABLE 14 SELECT LISTING OF PHARMACEUTICALS TO TREAT FUNGAL INFECTIONSBY NAME, TYPE AND MANUFACTURER, 2012 56TABLE 15 PROJECTED GLOBAL MARKET FOR PHARMACEUTICALS TO TREATFUNGAL HAI, THROUGH 2018 ($ MILLIONS) 57FIGURE 5 GLOBAL MARKET SHARES OF PHARMACEUTICALS TO TREAT FUNGAL HAIBY COMPANY, 2012 (%) 57GLOBAL OPPORTUNITIES 58GLOBAL GROWTH RATES FOR PHARMACEUTICALS 58ROLE OF EMERGING COUNTRIES IN GLOBAL MARKETS 58PHARMACEUTICAL SALES IN EMERGING NATIONS 58REGIONAL ANALYSIS 59TABLE 16 PROJECTED GLOBAL MARKET FOR HAI PHARMACEUTICALS BY REGION,THROUGH 2018 ($ MILLIONS) 59AMERICAS 59TABLE 17 PROJECTED AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTS TOCONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 60TABLE 18 PROJECTED AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTSDESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($MILLIONS)60FIGURE 6 AMERICAS HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE,2013 AND 2018 (%) 60EMRA 61TABLE 19 PROJECTED EMRA MARKET FOR PHARMACEUTICAL PRODUCTS TOCONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 62TABLE 20 PROJECTED EMRA MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNEDTO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH 2018 ($MILLIONS)63FIGURE 7 EMRA HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE, 2013AND 2018 (%) 64ASIA 64Hepatitis in Asian Region 65Hepatitis in Japan 65Hepatitis in China 65TABLE 21 PROJECTED ASIAN MARKET FOR PHARMACEUTICAL PRODUCTS TOCONTROL HAI, THROUGH 2018 ($ MILLIONS) 65TABLE 22 PROJECTED ASIAN MARKET FOR PHARMACEUTICAL PRODUCTSDESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH2018 ($ MILLIONS)66FIGURE 8 ASIAN HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE, 2013AND 2018 (%) 66

CHAPTER 5 HAI ENVIRONMENTAL TREATMENT MARKET 69

GLOBAL HAI ENVIRONMENTAL TREATMENT MARKET 69TABLE 23 PROJECTED GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTSDESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($MILLIONS)69AIR TREATMENT 69ROOM FILTRATION SYSTEMS 70ROOM PRESSURIZATION 70HYDROGEN PEROXIDE VAPOR (HPV) 71ULTRAVIOLET (UV) LIGHT DISINFECTION 71WATER TREATMENT 71DESIGN OF SINKS AND OTHER WATER FACILITIES 71LEVELS OF CLEANING 72ENVIRONMENTAL CLEANING 72DISINFECTION 72Levels of Disinfection 72TABLE 24 ADVANTAGES/DISADVANTAGES OF COMMONLY USED DISINFECTANTS 73Disinfectants 75Phenolics 75Oxidizing Agents 75Halogens 75Aldehydes 75Ortho-phthalaldehyde (OPA) 76Quaternary Ammonium Compounds 76Bleach 76Alcohols 76TABLE 25 PROJECTED GLOBAL MARKET FOR DISINFECTANT PRODUCTS DESIGNEDTO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 77FIGURE 9 GLOBAL MARKET SHARES OF DISINFECTANT PRODUCTS BY TYPE, 2012(%) 77Patient Skin Preparation Disinfectants 77Povidone-Iodine Solutions 78Chlorohexidine Gluconate 78TABLE 26 PROJECTED GLOBAL MARKET FOR PATIENT PREPARATIONDISINFECTANTS, THROUGH 2018 ($ MILLIONS) 79STERILIZATION SYSTEMS FOR INFECTION CONTROL 79TABLE 27 PROJECTED GLOBAL MARKET FOR STERILIZATION DESIGNED TOMINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 79FILTRATION 80CHEMICAL STERILIZATION 80EtO Sterilization 81Major Manufacturers in Chemical Sterilization 81STEAM STERILIZATION 81TABLE 28 SELECTED MATERIALS THAT RESPOND WELL TO STEAM STERILIZATION 82Autoclaving 82Major Players in Heat Sterilization 82ANTIMICROBIAL COPPER SURFACE COATINGS 82REGIONAL ANALYSIS 83TABLE 29 PROJECTED GLOBAL MARKET FOR ENVIRONMENTALPRODUCTS/EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 83FIGURE 10 GLOBAL MARKET SHARES OF ENVIRONMENTAL PRODUCTS TO MINIMIZEHAI BY PRODUCT, 2013 AND 2018 (%) 83AMERICAS 84TABLE 30 PROJECTED AMERICAS MARKET FOR ENVIRONMENTALPRODUCTS/EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 85TABLE 31 PROJECTED AMERICAS MARKET FOR ENVIRONMENTAL PRODUCTSDESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($MILLIONS)85EMRA 85TABLE 32 PROJECTED EMRA MARKET FOR ENVIRONMENTALPRODUCTS/EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 86TABLE 33 PROJECTED EMRA MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNEDTO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 86FIGURE 11 EMRA MARKET SHARE OF ENVIRONMENTAL PRODUCTS TO MINIMIZEHAI BY PRODUCT, 2013 AND 2018 (%) 86ASIA 87TABLE 34 PROJECTED ASIAN MARKET FOR ENVIRONMENTALPRODUCTS/EQUIPMENT TO CONTROL HAI, THROUGH 2018 ($ MILLIONS) 88TABLE 35 PROJECTED ASIAN MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNEDTO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 88FIGURE 12 ASIAN MARKET SHARE OF ENVIRONMENTAL PRODUCTS TO MINIMIZEHAI BY PRODUCT, 2013 AND 2018 (%) 88

CHAPTER 6 HAI MEDICAL DEVICES: CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILIZATION FILTERS 91

TABLE 36 PROJECTED GLOBAL MARKET FOR MEDICAL DEVICES THAT MINIMIZEHEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 91ANTIMICROBIAL COATINGS 91CATHETERS 91CATHETER COATINGS 92Common Antimicrobial Coatings 92Nitrofurazone 93Minocycline/Rifampin 93Silver Coating 93SURFACE-MODIFIED CATHETER 93GLOBAL HAI CATHETER MARKET 94TABLE 37 PROJECTED GLOBAL MARKET FOR CATHETERS WITH ANTIMICROBIALPROPERTIES, THROUGH 2018 ($ MILLIONS) 94FIGURE 13 PROJECTED HAI CATHETER MARKET SHARES BY URINARY, CVC, PICC,2013 AND 2018 (%) 95URINARY TRACT CATHETERS 95CENTRAL VENOUS CATHETERS 96Dialysis Catheters 96Catheter-Related Bloodstream Infections (CRBSI) 96PERIPHERALLY INSERTED CENTRAL VENOUS CATHETERS (PICC) 97MARKET OPPORTUNITIES FOR CATHETER MANUFACTURERS 97CATHETER GROWTH IN REGIONAL MARKETS 97TABLE 38 PROJECTED GLOBAL HAI CATHETER MARKET BY REGION, THROUGH2018 ($ MILLIONS) 98FIGURE 14 PROJECTED GLOBAL HAI CATHETER MARKET SHARES BY REGION, 2013AND 2018 (%) 98PATIENT VENTILATION DEVICES 99TABLE 39 PROJECTED GLOBAL MARKET FOR PATIENT VENTILATION PRODUCTS,THROUGH 2018 ($ MILLIONS) 100TYPES OF VENTILATION DEVICES 100Noninvasive Ventilators 100PATIENT VENTILATION MARKET 101TABLE 40 PROJECTED GLOBAL MARKET FOR NONINVASIVE VENTILATION SYSTEMSFOR USE WITH PATIENTS WHO HAVE HAI, THROUGH 2018 ($ MILLIONS) 101ENDOTRACHEAL TUBES AND VENTILATION SYSTEMS 101Coated Endotracheal Tubes 101Tapered Endotracheal Tubes 102TABLE 41 PROJECTED GLOBAL MARKET FOR COATED ENDOTRACHEAL TUBESDESIGNED TO MINIMIZE VAP, THROUGH 2018 ($ MILLIONS) 102IN-LINE STERILE IV FILTRATION 102TABLE 42 PROJECTED GLOBAL STERILE IV FILTER MARKET, THROUGH 2018 ($MILLIONS) 103REGIONAL ANALYSIS 103TABLE 43 PROJECTED GLOBAL MARKET FOR PATIENT INFECTION CONTROLDEVICES BY REGION, THROUGH 2018 ($ MILLIONS) 103FIGURE 15 GLOBAL HAI PATIENT INFECTION CONTROL DEVICES MARKET SHARESBY REGION, 2013 AND 2018 (%) 104THE AMERICAS 105TABLE 44 PROJECTED AMERICAS MARKET FOR HAI INFECTION CONTROL DEVICESBY REGION, THROUGH 2018 ($ MILLIONS) 105FIGURE 16 AMERICAS MARKET SHARES FOR CATHETERS, PATIENT VENTILATIONSYSTEMS AND IN-LINE STERILE FILTERS, 2013 AND 2018 (%) 105TABLE 45 PROJECTED AMERICAS MARKET FOR CATHETERS, PATIENT VENTILATIONSYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2018 ($ MILLIONS) 107FIGURE 17 AMERICAS MARKET SHARES OF CATHETERS, PATIENT VENTILATIONSYSTEMS AND IN-LINE STERILE FILTERS BY PRODUCT, 2013 AND 2018 (%) 107EMRA 108TABLE 46 PROJECTED EMRA MARKET FOR CATHETERS, PATIENT VENTILATIONSYSTEMS AND IN-LINE STERILE FILTERS BY REGION, THROUGH 2018 ($ MILLIONS) 108TABLE 47 PROJECTED EMRA MARKET FOR CATHETERS, PATIENT VENTILATIONSYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2018 ($ MILLIONS) 109FIGURE 18 EMRA MARKET SHARES OF CATHETERS, PATIENT VENTILATIONSYSTEMS AND IN-LINE STERILE FILTERS BY PRODUCT, 2013 AND 2018 (%) 109ASIA 110TABLE 48 PROJECTED ASIAN MARKET FOR CATHETERS, PATIENT VENTILATIONSYSTEMS AND IN-LINE STERILE FILTERS BY REGION, THROUGH 2018 ($ MILLIONS) 110TABLE 49 PROJECTED ASIAN MARKET FOR CATHETERS, PATIENT VENTILATIONSYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2018 ($ MILLIONS) 111FIGURE 19 ASIAN MARKET SHARES OF CATHETERS, PATIENT VENTILATIONSYSTEMS AND IN-LINE STERILE FILTERS BY PRODUCT, 2013 AND 2018 (%) 111

CHAPTER 7 REGULATIONS 114

AMERICAS 114CREATING DRUG TREATMENTS 114TABLE 50 PROCESS OF CREATING DRUG TREATMENTS IN THE U.S. 114U.S. INFECTION CONTROL PROGRAMS 115INFECTION CONTROL MEASURES/PROTOCOLS 115U.S. REGULATIONS 116HOSPITAL INFECTIONS DISCLOSURE ACT (HIDA) 116CURRENT AND PENDING REQUIREMENTS 116Affordable Care Act and Implications for the Pharmaceutical Industry 116Biosimilars 117CMS Reimbursement for HAI 117"Never Events" Reimbursement 117Generating Antibiotics Incentives Now Act (2012) 118BRAZILIAN REGULATIONS 118EUROPEAN REGULATIONS 119INNOVATIVE MEDICINES INITIATIVE (IMI) 119IMPLICATIONS FOR PHARMACEUTICAL MANUFACTURERS 119JAPANESE REGULATIONS 119CHINESE REGULATIONS 120

CHAPTER 8 CURRENT RESEARCH, EMERGING THERAPIES AND MARKET

OPPORTUNITIES 122EMERGING RESEARCH 122FIMD 122BROAD SPECTRUM ANTIVIRAL 122NEW ENGLAND CENTER OF EXCELLENCE (NERCE) 123PHARMACEUTICAL TREATMENT PRODUCT PIPELINE 123TABLE 51 HAI PHARMACEUTICAL PRODUCT PIPELINE 123FIGURE 20 MARKET SHARES BY TYPE OF PHARMACEUTICAL COMPOUND INDEVELOPMENT, 2012 (%) 127PHARMACEUTICAL RESEARCH 129BACTERIAL INFECTIONS: APPROVED TREATMENTS AND PRODUCTS INDEVELOPMENT 129Achaogen 129Rib-X Pharmaceuticals 129Wakamoto Pharmaceutical Co. Ltd. 129GlaxoSmithKline (GSK) 129Polyphor 130Rempex Pharmaceuticals 130Basilea Pharmaceuticals 130Cerexa 130Cubist Pharmaceuticals 131Merck 131Galapagos NV 131Optimer Pharmaceuticals 132GlaxoSmithKline 132Toyama Chemical 132Trius Therapeutics 132Crestone Pharma 133Boehringer Ingelheim 133Theravance 133The Medicines Company 134Paratek Pharmaceuticals 134VIRAL INFECTIONS: APPROVED TREATMENTS AND PRODUCTS INDEVELOPMENT 134BioCryst Pharmaceuticals 134ViiV Healthcare 134Roche 135Merck 135Toyama Chemical 135Daiichi Sankyo 136Gilead Sciences 136Janssen Pharmaceuticals/Johnson & Johnson 136Vertex 136FUNGAL INFECTIONS: APPROVED TREATMENTS AND PRODUCTS INDEVELOPMENT 136Basilea Pharmaceuticals 136ANTISEPTIC WASHES 137MEDICAL DEVICE DESIGN 137ANTIBACTERIAL, ANTIFOULING POLYMER COATINGS 137ONDINE BIOMEDICAL 137OPPORTUNITIES/CHALLENGES FOR HAI INDUSTRY 138MEDICAL DEVICE OPPORTUNITIES/CHALLENGES 138Challenges 138ENVIRONMENTAL AND STRUCTURAL OPPORTUNITIES/CHALLENGES 139Challenges 139PHARMACEUTICAL MARKET OPPORTUNITIES/CHALLENGES 139Patent Expiry 140TABLE 52 SELECTED HAI-RELATED PHARMACEUTICAL PATENT EXPIRATIONS,2005–2015 140Pipeline Limitations 140Regulatory Restrictions 141Generic Competition 141THE IMPACT OF DEMOGRAPHIC CHANGES 141DEMOGRAPHIC CHANGES IN THE U.S. 141DEMOGRAPHIC CHANGES OUTSIDE THE U.S. 142

CHAPTER 9 PATENTS 144

TABLE 53 NUMBER OF SELECTED PATENTS BY TYPE, 2008 THROUGH JULY 2013 144PATENTS BY DATE OF ISSUE 144TABLE 54 PHARMACEUTICAL PATENTS BY DATE OF ISSUE, JAN. 2008 THROUGHJULY 2013 145TABLE 55 ENVIRONMENTAL PATENTS BY DATE OF ISSUE, JAN. 2008 THROUGH JULY2013 145TABLE 56 MEDICAL DEVICE* PATENTS BY DATE OF ISSUE, JAN. 2008 THROUGHJULY 2013 145NUMBER OF PATENTS BY MANUFACTURER 145TABLE 57 NUMBER OF PATENTS BY MANUFACTURER, JAN. 2008 THROUGH JULY2013 146PHARMACEUTICALS 148BACTERIAL PHARMACEUTICAL PATENTS 148TABLE 58 PATENTS ON BACTERIAL PHARMACEUTICALS: NUMBER, COMPANY, TYPEOF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 THROUGH JULY2013149FUNGAL PHARMACEUTICAL PATENTS 160TABLE 59 PATENTS ON FUNGAL PHARMACEUTICALS: NUMBER, COMPANY, TYPE OFPHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JANUARY 2010 THROUGHDECEMBER 2012160VIRAL PHARMACEUTICAL PATENTS 160TABLE 60 PATENTS ON VIRAL PHARMACEUTICALS: NUMBER, COMPANY, TYPE OFPHARMACEUTICAL, DESCRIPTION, JAN. 2008 THROUGH JULY 2013 161ENVIRONMENTAL CONTROLS 162TABLE 61 PATENTS ON AIR FILTRATION: NUMBER, COMPANY, TYPE OFPHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE JULY 2012-MARCH 2013 163TABLE 62 PATENTS ON WATER TREATMENT: NUMBER, COMPANY, TYPE OFPHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE SEPT. 2010 TO JUNE 2013 164TABLE 63 PATENTS ON SOLID WASTE TREATMENT: NUMBER, COMPANY, TYPE OFPHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE APRIL 2013 165PATENTS FOR PATIENT DISINFECTION 166TABLE 64 PATENTS ON PATIENT DISINFECTANTS: NUMBER, COMPANY, TYPE OFPHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 TO JULY 2013 166PATENTS FOR SURFACE DISINFECTANTS 167TABLE 65 PATENTS ON SURFACE DISINFECTANTS: NUMBER, COMPANY, TYPE OFPHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 TO JULY 2013 167MEDICAL DEVICES 172TABLE 66 PATENTS ON CATHETERS: NUMBER, COMPANY, TYPE OFPHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JANUARY 2008 TO JULY 2012 172Antimicrobial Coatings 176TABLE 67 PATENTS ON ANTIMICROBIAL COATINGS: NUMBER, COMPANY, TYPE OFPHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 THROUGH JUNE 2013 177

CHAPTER 10 COMPANY DIRECTORY 187

PHARMACEUTICALS 187ABBOTT LABORATORIES 187Business Overview 187Products 187TABLE 68 ABBOTT HAI PRODUCTS 187ACHAOGEN INC. 188ASTELLAS PHARMA INC. 188Business Overview 188Products 188TABLE 69 ASTELLAS HAI PRODUCTS 188ASTRAZENECA PLC 189Business Overview 189Products 189TABLE 70 ASTRAZENECA HAI PRODUCTS 189B. BRAUN MELSUNGEN 189Business Overview 189Products 190TABLE 71 B. BRAUN HAI PRODUCTS 190BACTIGUARD AB 190Business Overview 190Products 190BASILEA PHARMACEUTICA LTD. 191Business Overview 191Products 191BAXTER INTERNATIONAL 191Business Overview 191BAYER AG (MILES-BAYER) 192Business Overview 192Products 192TABLE 72 BAYER HAI PRODUCTS 192BOEHRINGER INGELHEIM GMBH 192Business Overview 193Products 193TABLE 73 BOEHRINGER INGELHEIM HAI PRODUCTS 193BRISTOL-MYERS SQUIBB 193Business Overview 193Products 194TABLE 74 BRISTOL MYERS SQUIBB HAI PRODUCTS 194CEREXA INC. (FOREST LABORATORIES) 194Business Overview 194Products 194TABLE 75 CEREXA HAI PRODUCTS 194CUBIST PHARMACEUTICALS 195Business Overview 195Products 195TABLE 76 CUBIST HAI PRODUCTS 195DAIICHI SANKYO 195Business Overview 195Products 196TABLE 77 DAIICHI SANKYO HAI PRODUCT 196FOREST LABORATORIES 196Business Overview 196Products 196TABLE 78 FOREST LABORATORIES HAI PRODUCTS 196GILEAD SCIENCES 196Business Overview 197Products 197TABLE 79 GILEAD SCIENCES HAI PRODUCTS 197GLAXOSMITHKLINE 197Business Overview 197Products 198TABLE 80 GLAXOSMITHKLINE HAI PRODUCTS 198JOHNSON & JOHNSON 198Business Overview 198Products 199TABLE 81 JOHNSON & JOHNSON HAI PRODUCTS 199JANSSEN THERAPEUTICS (FORMERLY TIBOTEC THERAPEUTICS) 199Business Overview 199Products 200TABLE 82 JANSSEN THERAPEUTICS HAI PRODUCTS 200MERCK 200Business Overview 200Products 200TABLE 83 MERCK HAI PRODUCTS 200NOVARTIS PHARMACEUTICALS 201Business Overview 201Products 201TABLE 84 NOVARTIS HAI PRODUCTS 201PFIZER 202Business Overview 202Products 202TABLE 85 PFIZER HAI PRODUCTS 202REMPEX PHARMACEUTICALS 203Business Overview 203RIB-X PHARMACEUTICALS 203Business Overview 203ROCHE PHARMACEUTICALS 204Business Overview 204Products 204TABLE 87 ROCHE HAI PHARMACEUTICAL PRODUCTS 204ROMARK LABORATORIES 204Business Overview 204SCHERING-PLOUGH (SEE MERCK) 205TETRAPHASE PHARMACEUTICALS 205Business Overview 205THERAVANCE 205Business Overview 205Products 206TABLE 88 THERAVANCE HAI PRODUCTS 206TOYAMA CHEMICAL CO. LTD. 206Business Overview 206Products 206TABLE 89 TOYAMA CHEMICAL HAI PRODUCTS 206VENUS REMEDIES LTD. 207Business Overview 207Products 207TABLE 90 VENUS REMEDIES HAI PRODUCTS 207VERTEX PHARMACEUTICALS INC. 207Business Overview 207Products 208TABLE 91 VERTEX HAI PRODUCTS 208VIIV HEALTHCARE 208Business Overview 208Products 208TABLE 92 VII HEALTHCARE HAI PRODUCTS 208VIROPHARMA INC. 209Business Overview 209Products 209TABLE 93 VIROPHARMA HAI PRODUCTS 209ENVIRONMENTAL PRODUCTS 2093M HEALTHCARE, MEDICAL DIVISION 209Business Overview 209Products 210ADVANCED STERILIZATION PRODUCTS 210Business Overview 210Products 210ANDERSEN PRODUCTS INC. 211Business Overview 211Products 211ECOLAB 211Business Overview 211Products 211GETINGE USA INC. 212Business Overview 212Products 212PRIMUS STERILIZER CO. INC. 212Business Overview 212Products 212RUHOF CORP. 213Business Overview 213Products 213STERIGENICS INTERNATIONAL INC. 213Business Overview 213Products 213SEALED AIR CORP. (DIVERSEY INC.) 214Business Overview 214Products 214STERIS CORP. 214Business Overview 214Products 214TUTTNAUER USA CO. LTD. 215Business Overview 215Products 215ULTRAVIOLET DEVICES INC. 215Business Overview 215Products 215XENEX HEALTHCARE SERVICES 216Business Overview 216Products 216INFECTION CONTROL DEVICES 216B BRAUN MELSUNGEN AG 216Business Overview 217Products 217BECTON DICKINSON 217Business Overview 217Products 217CANTEL MEDICAL CORP. 218Business Overview 218Products 218CAREFUSION CORP. 219Business Overview 219Products 219CLOROX CO. 219Business Overview 219Products 219COLOPLAST GROUP 220Business Overview 220Products 220COOK MEDICAL 220Business Overview 220Products 220COVIDIEN PLC 221Business Overview 221Products 221C.R. BARD 221Business Overview 221Products 222KIMBERLY-CLARK HEALTHCARE 222Business Overview 222Products 222ONDINE BIOMEDICAL INC. 222Business Overview 222Products 223ROCHESTER MEDICAL LTD. 223Business Overview 223Products 223TELEFLEX MEDICAL 223Business Overview 223Products 224WELCH ALLYN INC. 224Business Overview 224Products 224WELLSPECT HEALTHCARE (FORMERLY ASTRA TECH INC.) 224

LIST OF TABLES

SUMMARY TABLE GLOBAL MARKET FOR SELECTED HAI TREATMENTS, THROUGH

2018 ($ MILLIONS) 7

TABLE 1 CAUSES AND TYPES OF HEALTHCARE-ACQUIRED INFECTIONS 12

TABLE 2 SELECTED RESPONSIBILITIES OF INFECTION CONTROL TEAM MEMBERS 24

TABLE 3 MAIN STEPS AND COMPONENTS IN DEVELOPING AN EFFECTIVE INFECTION

CONTROL SURVEILLANCE SYSTEM 26

TABLE 4 CDC MEASURES FOR PREVENTION OF HEALTHCARE-ACQUIRED INFECTIONS 30

TABLE 5 GOALS TO REDUCE HAI IN U.S. HOSPITALS BY 2013 32

TABLE 6 DECREASE IN HAI IN U.S. HOSPITAL SETTINGS, 2008–2010 (%) 32

TABLE 7 SELECTED MERGERS AND/OR ACQUISITIONS, 2008-2013 ($ MILLIONS) 36

TABLE 8 PROJECTED GLOBAL MARKET FOR HAI PHARMACEUTICALS BY TYPE,

THROUGH 2018 ($ MILLIONS) 39

TABLE 9 SELECTED VIRAL HAI PHARMACEUTICALS BY NAME, INDICATION AND

MANUFACTURER, 2010 40

TABLE 10 PROJECTED GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT VIRAL

HAI BY CONDITION, THROUGH 2018 ($ MILLIONS) 44

TABLE 11 ANTIBIOTIC RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED 49

TABLE 12 SELECTED BACTERIAL HAI PHARMACEUTICALS BY NAME, INDICATION AND

MANUFACTURER, 2012 49

TABLE 13 PROJECTED GLOBAL MARKET FOR TO TREAT BACTERIAL HAI, THROUGH

2018 ($ MILLIONS) 56

TABLE 14 SELECT LISTING OF PHARMACEUTICALS TO TREAT FUNGAL INFECTIONS

BY NAME, TYPE AND MANUFACTURER, 2012 56

TABLE 15 PROJECTED GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT FUNGAL

HAI, THROUGH 2018 ($ MILLIONS) 57

TABLE 16 PROJECTED GLOBAL MARKET FOR HAI PHARMACEUTICALS BY REGION,

THROUGH 2018 ($ MILLIONS) 59

TABLE 17 PROJECTED AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTS TO

CONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 60

TABLE 18 PROJECTED AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTS

DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($

MILLIONS)

60

TABLE 19 PROJECTED EMRA MARKET FOR PHARMACEUTICAL PRODUCTS TO

CONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 62

TABLE 20 PROJECTED EMRA MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED

TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH 2018 ($

MILLIONS)

63

TABLE 21 PROJECTED ASIAN MARKET FOR PHARMACEUTICAL PRODUCTS TO

CONTROL HAI, THROUGH 2018 ($ MILLIONS) 65

TABLE 22 PROJECTED ASIAN MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED

TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH 2018 ($

MILLIONS)

66

TABLE 23 PROJECTED GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED

TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 69

TABLE 24 ADVANTAGES/DISADVANTAGES OF COMMONLY USED DISINFECTANTS 73

TABLE 25 PROJECTED GLOBAL MARKET FOR DISINFECTANT PRODUCTS DESIGNED

TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 77

TABLE 26 PROJECTED GLOBAL MARKET FOR PATIENT PREPARATION DISINFECTANTS,

THROUGH 2018 ($ MILLIONS) 79

TABLE 27 PROJECTED GLOBAL MARKET FOR STERILIZATION DESIGNED TO MINIMIZE

HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 79

TABLE 28 SELECTED MATERIALS THAT RESPOND WELL TO STEAM STERILIZATION 82

TABLE 29 PROJECTED GLOBAL MARKET FOR ENVIRONMENTAL

PRODUCTS/EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 83

TABLE 30 PROJECTED AMERICAS MARKET FOR ENVIRONMENTAL

PRODUCTS/EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 85

TABLE 31 PROJECTED AMERICAS MARKET FOR ENVIRONMENTAL PRODUCTS

DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($

MILLIONS)

85

TABLE 32 PROJECTED EMRA MARKET FOR ENVIRONMENTAL PRODUCTS/EQUIPMENT

TO CONTROL HAI BY REGION, THROUGH 2018 ($ MILLIONS) 86

TABLE 33 PROJECTED EMRA MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED

TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 86

TABLE 34 PROJECTED ASIAN MARKET FOR ENVIRONMENTAL PRODUCTS/EQUIPMENT

TO CONTROL HAI, THROUGH 2018 ($ MILLIONS) 88

TABLE 35 PROJECTED ASIAN MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED

TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 88

TABLE 36 PROJECTED GLOBAL MARKET FOR MEDICAL DEVICES THAT MINIMIZE

HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 ($ MILLIONS) 91

TABLE 37 PROJECTED GLOBAL MARKET FOR CATHETERS WITH ANTIMICROBIAL

PROPERTIES, THROUGH 2018 ($ MILLIONS) 94

TABLE 38 PROJECTED GLOBAL HAI CATHETER MARKET BY REGION, THROUGH 2018

($ MILLIONS) 98

TABLE 39 PROJECTED GLOBAL MARKET FOR PATIENT VENTILATION PRODUCTS,

THROUGH 2018 ($ MILLIONS) 100

TABLE 40 PROJECTED GLOBAL MARKET FOR NONINVASIVE VENTILATION SYSTEMS

FOR USE WITH PATIENTS WHO HAVE HAI, THROUGH 2018 ($ MILLIONS) 101

TABLE 41 PROJECTED GLOBAL MARKET FOR COATED ENDOTRACHEAL TUBES

DESIGNED TO MINIMIZE VAP, THROUGH 2018 ($ MILLIONS) 102

TABLE 42 PROJECTED GLOBAL STERILE IV FILTER MARKET, THROUGH 2018 ($

MILLIONS) 103

TABLE 43 PROJECTED GLOBAL MARKET FOR PATIENT INFECTION CONTROL DEVICES

BY REGION, THROUGH 2018 ($ MILLIONS) 103

TABLE 44 PROJECTED AMERICAS MARKET FOR HAI INFECTION CONTROL DEVICES BY

REGION, THROUGH 2018 ($ MILLIONS) 105

TABLE 45 PROJECTED AMERICAS MARKET FOR CATHETERS, PATIENT VENTILATION

SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2018 ($ MILLIONS) 107

TABLE 46 PROJECTED EMRA MARKET FOR CATHETERS, PATIENT VENTILATION

SYSTEMS AND IN-LINE STERILE FILTERS BY REGION, THROUGH 2018 ($ MILLIONS) 108

TABLE 47 PROJECTED EMRA MARKET FOR CATHETERS, PATIENT VENTILATION

SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2018 ($ MILLIONS) 109

TABLE 48 PROJECTED ASIAN MARKET FOR CATHETERS, PATIENT VENTILATION

SYSTEMS AND IN-LINE STERILE FILTERS BY REGION, THROUGH 2018 ($ MILLIONS) 110

TABLE 49 PROJECTED ASIAN MARKET FOR CATHETERS, PATIENT VENTILATION

SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2018 ($ MILLIONS) 111

TABLE 50 PROCESS OF CREATING DRUG TREATMENTS IN THE U.S. 114

TABLE 51 HAI PHARMACEUTICAL PRODUCT PIPELINE 123

TABLE 52 SELECTED HAI-RELATED PHARMACEUTICAL PATENT EXPIRATIONS,

2005–2015 140

TABLE 53 NUMBER OF SELECTED PATENTS BY TYPE, 2008 THROUGH JULY 2013 144

TABLE 54 PHARMACEUTICAL PATENTS BY DATE OF ISSUE, JAN. 2008 THROUGH JULY

2013 145

TABLE 55 ENVIRONMENTAL PATENTS BY DATE OF ISSUE, JAN. 2008 THROUGH JULY

2013 145

TABLE 56 MEDICAL DEVICE* PATENTS BY DATE OF ISSUE, JAN. 2008 THROUGH JULY

2013 145

TABLE 57 NUMBER OF PATENTS BY MANUFACTURER, JAN. 2008 THROUGH JULY

2013 146

TABLE 58 PATENTS ON BACTERIAL PHARMACEUTICALS: NUMBER, COMPANY, TYPE

OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 THROUGH JULY

2013

149

TABLE 59 PATENTS ON FUNGAL PHARMACEUTICALS: NUMBER, COMPANY, TYPE OF

PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JANUARY 2010 THROUGH

DECEMBER 2012

160

TABLE 60 PATENTS ON VIRAL PHARMACEUTICALS: NUMBER, COMPANY, TYPE OF

PHARMACEUTICAL, DESCRIPTION, JAN. 2008 THROUGH JULY 2013 161

TABLE 61 PATENTS ON AIR FILTRATION: NUMBER, COMPANY, TYPE OF

PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE JULY 2012-MARCH 2013 163

TABLE 62 PATENTS ON WATER TREATMENT: NUMBER, COMPANY, TYPE OF

PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE SEPT. 2010 TO JUNE 2013 164

TABLE 63 PATENTS ON SOLID WASTE TREATMENT: NUMBER, COMPANY, TYPE OF

PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE APRIL 2013 165

TABLE 64 PATENTS ON PATIENT DISINFECTANTS: NUMBER, COMPANY, TYPE OF

PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 TO JULY 2013 166

TABLE 65 PATENTS ON SURFACE DISINFECTANTS: NUMBER, COMPANY, TYPE OF

PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 TO JULY 2013 167

TABLE 66 PATENTS ON CATHETERS: NUMBER, COMPANY, TYPE OF

PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JANUARY 2008 TO JULY 2012 172

TABLE 67 PATENTS ON ANTIMICROBIAL COATINGS: NUMBER, COMPANY, TYPE OF

PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 THROUGH JUNE 2013 177

TABLE 68 ABBOTT HAI PRODUCTS 187

TABLE 69 ASTELLAS HAI PRODUCTS 188

TABLE 70 ASTRAZENECA HAI PRODUCTS 189

TABLE 71 B. BRAUN HAI PRODUCTS 190

TABLE 72 BAYER HAI PRODUCTS 192

TABLE 73 BOEHRINGER INGELHEIM HAI PRODUCTS 193

TABLE 74 BRISTOL MYERS SQUIBB HAI PRODUCTS 194

TABLE 75 CEREXA HAI PRODUCTS 194

TABLE 76 CUBIST HAI PRODUCTS 195

TABLE 7

To order this report: Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products http://www.reportlinker.com/p0619272/Healthcare-Acquired-Infection-Devices-Pharmaceuticals-and-Environmental-Products.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply

__________________________
Contact Clare: [email protected]: (339)-368-6001Intl: +1 339-368-6001

SOURCE Reportlinker

21%

more press release views with 

Request a Demo